ViCentra — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

ViCentra is a commercial-stage medical device company focused on reinventing insulin pump therapy for people with diabetes. Its flagship product, the Kaleido pump, distinguishes itself through a modular, reusable design, extensive personalization options, and integration with third-party algorithms and continuous glucose monitors to form a hybrid closed-loop system. The company currently markets its solution in the Netherlands and Germany, targeting improved quality of life and glycemic control through a patient-centric, sustainable approach to durable medical equipment.

Diabetes

Technology Platform

Kaleido insulin pump platform featuring a miniaturized, reusable, waterproof patch pump with customizable color options and flexible wearability. It integrates with third-party hybrid closed-loop algorithms (Diabeloop's DBLG1) and continuous glucose monitors (Dexcom G6) to enable automated insulin delivery and data visualization via a cloud platform.

Opportunities

The growing global diabetes population and demand for more discreet, user-friendly, and automated insulin delivery systems present a significant market opportunity.

ViCentra's focus on design, sustainability, and lifestyle integration allows it to target a specific segment of users underserved by traditional medical-looking devices, while its hybrid closed-loop capability addresses the critical need for improved glycemic control.

Risk Factors

ViCentra faces intense competition from larger, established insulin pump manufacturers with greater resources and market access.

Its commercial success is also dependent on third-party technologies (Diabeloop algorithm, Dexcom CGM), creating partnership and integration risks.

Scaling operations and securing reimbursement in new geographic markets will be a major financial and operational challenge.

Competitive Landscape

ViCentra competes in the insulin pump and hybrid closed-loop system market against major players like Insulet (Omnipod series), Tandem Diabetes Care (t:slim X2 with Control-IQ), and Medtronic (MiniMed series). Its differentiation is based on hardware design (small size, color customization, reusable pump), lifestyle flexibility, and its specific partnership with Diabeloop's algorithm, positioning it as a niche, user-experience-focused alternative.

More companies in Digital Health & Biotech SaaS →More companies in Netherlands →